ArticleBMC cancer2020
The prognostic value of neuromedin U in patients with hepatocellular carcinoma.
Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Mechanisms of neuropeptide-mediated immune sensing in the modulation of antitumor immunity.Journal for immunotherapy of cancer · 2026Review
- Pharmacological Blockade of NMUR2 Suppresses Glioma Growth by Inhibiting STAT5-Mediated Transcription of Cell Cycle-associated Genes.International journal of biological sciences · 2026Article
- Neuromedin U receptor 1 deletion leads to impaired immunotherapy response and high malignancy in colorectal cancer.iScience · 2024Article
- Neuromedin U regulates the anti-tumor activity of CD8Cancer science · 2024Article
- Neuromedin U secreted by colorectal cancer cells promotes a tumour-supporting microenvironment.Cell communication and signaling : CCS · 2022Article
- Expression ofTranslational cancer research · 2022Article
- Neuromedin U induces an invasive phenotype in CRC cells expressing the NMUR2 receptor.Journal of experimental & clinical cancer research : CR · 2021Article
- Macrophage Polarization and Its Role in Liver Disease.Frontiers in immunology · 2021Review
- NMU Is a Poor Prognostic Biomarker in Patients with Lung Adenocarcinoma.Disease markers · 2021Article
- Identification of an extracellular vesicle-related gene signature in the prediction of pancreatic cancer clinical prognosis.Bioscience reports · 2020Article
- Identification of Potential Key Genes and Pathways in Enzalutamide-Resistant Prostate Cancer Cell Lines: A Bioinformatics Analysis with Data from the Gene Expression Omnibus (GEO) Database.BioMed research international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundNeuromedin U (NMU) is a neuropeptide belonging to the neuromedin family. Recently, significant associations between NMU and several cancers have been reported. However, no studies have examined the association between NMU and hepatocellular carcinoma (HCC). The purpose of this study was to examine the role of NMU in HCC.
methodsAn enzyme-linked immunosorbent assay was used to measure the level of NMU protein in the sera of patients with hepatic hemangioma and HCC. NMU and cytokine mRNA expression was assessed in HCC samples via RT-qPCR. A tissue microarray consisting of 228 HCC peri- and intra-tumor tissues was used to detect NMU expression via immunohistochemical analysis. The association between NMU expression and overall survival (OS) and disease-free survival (DFS) was analyzed by Kaplan-Meier curves, the log-rank test, and Cox proportional hazard model.
resultsThe level of NMU protein was increased in the sera of HCC patients (p = 0.006). NMU was expressed in intercellular space, rather than in hepatocytes or HCC cells. The prognosis of HCC patients with high NMU expression in peri-tumor tissue was significantly poorer than that of patients with low NMU expression (OS: p = 0.002, DFS: p = 0.033). Peri-tumor NMU expression was also a significant independent prognostic factor for OS (hazard ratio: 1.541, 95% confidence interval: 1.092-2.175, p = 0.014). The level of NMU expression was positively associated with M2 macrophage percentage and the levels of type-2 inflammatory cytokines in HCC tissue.
conclusionsNMU may serve as a novel prognostic biomarker for HCC patients, although further validation is needed in the future. The activation of M2 macrophages and a type-2 inflammatory response may involve in the role of NMU in patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.